公开(公告)号：US08071288B2

公开(公告)日：2011-12-06

申请号：US12030024

申请日：2008-02-12

申请人： Larry Gold ,  Jonathan Drew Smith ,  Dominic Zichi ,  Daniel J. Schneider ,  Chad Greef

发明人： Larry Gold ,  Jonathan Drew Smith ,  Dominic Zichi ,  Daniel J. Schneider ,  Chad Greef

IPC分类号： C12Q1/68 ,  C07K14/00

CPC分类号： C12N15/115 ,  G01N33/58

摘要： The present invention provides novel methods and reagents for detecting the binding of protein targets to nucleic acid ligands. Using Universal Protein Stains (UPS), proteins bound by nucleic acid ligands may be labeled with a detectable moiety. The methods and reagents are particularly useful for the detection of protein targets bound to multiplexed arrays of nucleic acid ligands. The present invention also provides novel methods for the multiplexed evaluation of photocrosslinking nucleic acid ligands. The methods allow one simultaneously to: (1) evaluate the performance (dynamic range) of a plurality of photocrosslinking nucleic acid ligands; and (2) assess the specificity of each photocrosslinking nucleic acid ligand for its cognate target protein. Photocrosslinking nucleic acid ligands with the most desirable properties can then be selected for use in diagnostic and prognostic medical assays. The present invention also provides a photocrosslinking nucleic acid ligand that binds specifically to HIV gp120MN.

摘要翻译： 本发明提供用于检测蛋白质靶标与核酸配体的结合的新型方法和试剂。 使用通用蛋白污渍（UPS），可以用可检测的部分标记由核酸配体结合的蛋白质。 所述方法和试剂对于检测与核酸配体复合阵列结合的蛋白质靶标特别有用。 本发明还提供了用于光交联核酸配体的多重评价的新方法。 该方法同时允许：（1）评估多个光交联核酸配体的性能（动态范围）; 和（2）评估每个光交联核酸配体对其同源靶蛋白的特异性。 然后可以选择具有最理想特性的光交联核酸配体用于诊断和预后医学测定。 本发明还提供了与HIV gp120MN特异性结合的光交联核酸配体。

公开(公告)号：US20100086948A1

公开(公告)日：2010-04-08

申请号：US12574341

申请日：2009-10-06

申请人： Larry Gold ,  Marty Stanton ,  Edward N. Brody ,  Rachel M. Ostroff ,  Dominic Zichi ,  Alex A.E. Stewart

发明人： Larry Gold ,  Marty Stanton ,  Edward N. Brody ,  Rachel M. Ostroff ,  Dominic Zichi ,  Alex A.E. Stewart

IPC分类号： G01N33/567 ,  G01N33/53 ,  G06F19/00 ,  G06F17/18

CPC分类号： G01N33/57449 ,  G16B40/00 ,  Y10T436/143333

摘要： The present application includes biomarkers, methods, devices, reagents, systems, and kits for the detection and diagnosis of ovarian cancer. In one aspect, the application provides biomarkers that can be used alone or in various combinations to diagnose ovarian cancer or permit the differential diagnosis of a pelvic mass as benign or malignant. In another aspect, methods are provided for diagnosing ovarian cancer in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 1, wherein the individual is classified as having ovarian cancer, or the likelihood of the individual having ovarian cancer is determined, based on the at least one biomarker value.

公开(公告)号：US20060057573A1

公开(公告)日：2006-03-16

申请号：US10504696

申请日：2003-02-10

申请人： Larry Gold ,  Jonathan Smith ,  Dominic Zichi ,  Daniel Schneider ,  Chad Greef

发明人： Larry Gold ,  Jonathan Smith ,  Dominic Zichi ,  Daniel Schneider ,  Chad Greef

IPC分类号： C12Q1/68 ,  C12Q1/42

CPC分类号： C12N15/115 ,  G01N33/58

摘要： The present invention provides novel methods and reagents for detecting the binding of protein targets to nucleic acid ligands. Using Universal Protein Stains (UPS), proteins bound by nucleic acid ligands may be labeled with a detectable moiety. The methods and reagents are particularly useful for the detection of protein targets bound to multiplexed arrays of nucleic acid ligands. The present invention also provides novel methods for the multiplexed evaluation of photocrosslinking nucleic acid ligands. The methods allow one simultaneously to: (1) evaluate the performance (dynamic range) of a plurality of photocrosslinking nucleic acid ligands; and (2) assess the specificity of each photocrosslinking nucleic acid ligand for its cognate target protein. Photocrosslinking nucleic acid ligands with the most desirable properties can then be selected for use in diagnostic and prognostic medical assays. The present invention also provides a photocrosslinking nucleic acid ligand that binds specifically to HIV gp120MN.

摘要翻译： 本发明提供用于检测蛋白质靶标与核酸配体的结合的新型方法和试剂。 使用通用蛋白污渍（UPS），可以用可检测的部分标记由核酸配体结合的蛋白质。 所述方法和试剂对于检测与核酸配体复合阵列结合的蛋白质靶标特别有用。 本发明还提供了用于光交联核酸配体的多重评价的新方法。 该方法同时允许：（1）评估多个光交联核酸配体的性能（动态范围）; 和（2）评估每个光交联核酸配体对其同源靶蛋白的特异性。 然后可以选择具有最理想特性的光交联核酸配体用于诊断和预后医学测定。 本发明还提供了与HIV gp120MN特异性结合的光交联核酸配体。

公开(公告)号：US20120143805A1

公开(公告)日：2012-06-07

申请号：US13390648

申请日：2010-03-05

申请人： Larry Gold ,  Edward N. Brody ,  Rachel M. Ostroff ,  Dominic Zichi ,  Alex A.E. Stewart ,  Michael Riel-Mehan ,  Mark Messenbaugh ,  Randee S. Schwartz ,  Jeffery Walker ,  Stephen Alaric Williams ,  Malti Nikrad

发明人： Larry Gold ,  Edward N. Brody ,  Rachel M. Ostroff ,  Dominic Zichi ,  Alex A.E. Stewart ,  Michael Riel-Mehan ,  Mark Messenbaugh ,  Randee S. Schwartz ,  Jeffery Walker ,  Stephen Alaric Williams ,  Malti Nikrad

IPC分类号： G06N5/00 ,  C40B30/04

CPC分类号： G01N33/57423 ,  G01N33/574 ,  G01N2800/60 ,  G16H50/20

摘要： The present disclosure includes biomarkers, methods, devices, reagents, systems, and kits for the detection and diagnosis of cancer. In one aspect, the disclosure provides biomarkers that can be used alone or in various combinations to diagnose cancer. In another aspect, methods are provided for diagnosing cancer in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 47, wherein the individual is classified as having cancer, or the likelihood of the individual having cancer is determined, based on the at least one biomarker value.

摘要翻译： 本公开包括用于癌症的检测和诊断的生物标志物，方法，装置，试剂，系统和试剂盒。 一方面，本公开提供可以单独使用或以各种组合使用以诊断癌症的生物标志物。 在另一方面，提供了用于诊断个体癌症的方法，其中所述方法包括在来自个体的生物样品中检测至少一个对应于选自表47中提供的生物标志物组的生物标志物的生物标记值， 其中所述个体基于所述至少一种生物标志物值被分类为具有癌症或确定个体患有癌症的可能性。

公开(公告)号：US20070166742A1

公开(公告)日：2007-07-19

申请号：US11623822

申请日：2007-01-17

申请人： Larry Gold ,  Dominic Zichi

发明人： Larry Gold ,  Dominic Zichi

IPC分类号： C12Q1/68 ,  C12M3/00

CPC分类号： C12Q1/6839 ,  C07B2200/11 ,  C12Q1/6834 ,  C12Q1/6837 ,  C40B40/00 ,  Y10S977/924 ,  C12Q2565/514 ,  C12Q2565/101 ,  C12Q2541/101 ,  C12Q2525/205

摘要： A nucleic acid ligand “biochip” is disclosed, consisting of a solid support to which one or more specific nucleic acid ligands is attached in a spatially defined manner. Each nucleic acid ligand binds specifically and avidly to a particular target molecule contained within a test mixture, such as a bodily fluid. The target molecules include, but are not limited to, proteins (cellular, viral, bacterial, etc.) hormones, sugars, metabolic byproducts, cofactor, and intermediates, drugs, and toxins. Contacting the test mixture with the biochip leads to the binding of a target molecule to its cognate nucleic acid ligand. The biochip may then be contacted with a reagent(s) that reacts covalently with proteins and not with nucleic acids. Each protein target in the test mixture may then detected by detecting the presence of the reagent at the appropriate address on the biochip.

摘要翻译： 公开了一种核酸配体“生物芯片”，其由以空间限定的方式连接一个或多个特定核酸配体的固体支持物组成。 每个核酸配体特异性地并且强烈地结合到测试混合物（例如体液）中所含的特定靶分子。 靶分子包括但不限于蛋白质（细胞，病毒，细菌等）激素，糖，代谢副产物，辅因子和中间体，药物和毒素。 将测试混合物与生物芯片接触导致靶分子与其同源核酸配体的结合。 然后生物芯片可以与与蛋白质共价反应的试剂与不与核酸反应的试剂接触。 然后可以通过检测生物芯片上适当地址处的试剂的存在来检测测试混合物中的每个蛋白质靶标。

公开(公告)号：US20100221752A2

公开(公告)日：2010-09-02

申请号：US12574341

申请日：2009-10-06

申请人： Larry Gold ,  Marty Stanton ,  Edward Brody ,  Rachel Ostroff ,  Dominic Zichi ,  Alex Stewart

发明人： Larry Gold ,  Marty Stanton ,  Edward Brody ,  Rachel Ostroff ,  Dominic Zichi ,  Alex Stewart

IPC分类号： G01N33/567 ,  G01N33/53 ,  G06F19/00 ,  G06F17/18

CPC分类号： G01N33/57449 ,  G06F19/24 ,  Y10T436/143333

摘要： The present application includes biomarkers, methods, devices, reagents, systems, and kits for the detection and diagnosis of ovarian cancer. In one aspect, the application provides biomarkers that can be used alone or in various combinations to diagnose ovarian cancer or permit the differential diagnosis of a pelvic mass as benign or malignant. In another aspect, methods are provided for diagnosing ovarian cancer in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 1, wherein the individual is classified as having ovarian cancer, or the likelihood of the individual having ovarian cancer is determined, based on the at least one biomarker value.

摘要翻译： 本申请包括用于卵巢癌的检测和诊断的生物标志物，方法，装置，试剂，系统和试剂盒。 一方面，本申请提供可以单独使用或以各种组合使用以诊断卵巢癌或允许骨盆块的鉴别诊断为良性或恶性的生物标志物。 在另一方面，提供了用于诊断个体中的卵巢癌的方法，其中所述方法包括在来自个体的生物样品中检测至少一种对应于选自表1中提供的生物标志物组的至少一种生物标志物的生物标记值 ，其中基于所述至少一种生物标志物值将所述个体分类为具有卵巢癌或确定具有卵巢癌的个体的可能性。

公开(公告)号：US20050112585A1

公开(公告)日：2005-05-26

申请号：US10719894

申请日：2003-11-21

申请人： Dominic Zichi ,  Larry Gold

发明人： Dominic Zichi ,  Larry Gold

IPC分类号： C12Q1/68 ,  G01N20060101 ,  G01N33/543

CPC分类号： G01N33/54393

摘要： The invention provides general methods for adjusting the inherent quantification range of a particular set of analytes in assays that employ capture reagents immobilized on solid supports. Specifically, the quantification range of a given analyte is adjusted to higher concentration regions by the addition of free capture reagent specific for that analyte, leaving the range of the remaining analytes the same and thereby permitting the simultaneous and accurate quantification of a plurality of analytes over a wide range of concentration values.

摘要翻译： 本发明提供了在使用固定在固体支持物上的捕获试剂的测定中调整特定分析物组的固有量化范围的一般方法。 具体来说，通过添加对该分析物特异性的游离捕获试剂，将给定分析物的定量范围调整到较高的浓度区域，使剩余分析物的范围保持不变，从而允许多个分析物同时且准确地定量 范围广泛的浓度值。

公开(公告)号：US10359425B2

公开(公告)日：2019-07-23

申请号：US12556480

申请日：2009-09-09

申请人： Larry Gold ,  Marty Stanton ,  Edward N. Brody ,  Rachel M. Ostroff ,  Dominic Zichi ,  Alex A. E. Stewart

发明人： Larry Gold ,  Marty Stanton ,  Edward N. Brody ,  Rachel M. Ostroff ,  Dominic Zichi ,  Alex A. E. Stewart

IPC分类号： G01N33/574

摘要： The present application includes biomarkers, methods, devices, reagents, systems, and kits for the detection and diagnosis of lung cancer. In one aspect, the application provides biomarkers that can be used alone or in various combinations to diagnose lung cancer or permit the differential diagnosis of pulmonary nodules as benign or malignant. In another aspect, methods are provided for diagnosing lung cancer in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 1, Col. 2, wherein the individual is classified as having lung cancer, or the likelihood of the individual having lung cancer is determined, based on the at least one biomarker value.

公开(公告)号：US20120165217A1

公开(公告)日：2012-06-28

申请号：US13391794

申请日：2010-04-03

申请人： Larry Gold ,  Edward N. Brody ,  Rachel M. Ostroff ,  Dominic Zichi ,  Alex A.E. Stewart ,  Michael Riel-Mehan ,  Mark Messenbaugh ,  Randee S. Schwartz ,  Jeffery Walker ,  Stephen Alaric Williams ,  Malti Nikrad

发明人： Larry Gold ,  Edward N. Brody ,  Rachel M. Ostroff ,  Dominic Zichi ,  Alex A.E. Stewart ,  Michael Riel-Mehan ,  Mark Messenbaugh ,  Randee S. Schwartz ,  Jeffery Walker ,  Stephen Alaric Williams ,  Malti Nikrad

IPC分类号： C40B30/04 ,  G06F19/00

CPC分类号： G01N33/57449 ,  G16B40/00

摘要： The present disclosure includes biomarkers, methods, devices, reagents, systems, and kits for the detection and diagnosis of cancer. In one aspect, the disclosure provides biomarkers that can be used alone or in various combinations to diagnose cancer. In another aspect, methods are provided for diagnosing cancer in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 24, wherein the individual is classified as having cancer, or the likelihood of the individual having cancer is determined, based on the at least one biomarker value.

摘要翻译： 本公开包括用于癌症的检测和诊断的生物标志物，方法，装置，试剂，系统和试剂盒。 一方面，本公开提供可以单独使用或以各种组合使用以诊断癌症的生物标志物。 在另一方面，提供了用于诊断个体癌症的方法，其中所述方法包括在来自个体的生物样品中检测至少一种对应于选自表24中提供的生物标志物组的生物标志物的生物标记值， 其中所述个体基于所述至少一种生物标志物值被分类为具有癌症或确定个体患有癌症的可能性。

公开(公告)号：US20100209935A1

公开(公告)日：2010-08-19

申请号：US12771895

申请日：2010-04-30

申请人： Larry Gold ,  Dominic Zichi

发明人： Larry Gold ,  Dominic Zichi

IPC分类号： C12Q1/68

CPC分类号： C12Q1/6839 ,  C07B2200/11 ,  C12Q1/6834 ,  C12Q1/6837 ,  C40B40/00 ,  Y10S977/924 ,  C12Q2565/514 ,  C12Q2565/101 ,  C12Q2541/101 ,  C12Q2525/205

摘要： A nucleic acid ligand “biochip” is disclosed, consisting of a solid support to which one or more specific nucleic acid ligands is attached in a spatially defined manner. Each nucleic acid ligand binds specifically and avidly to a particular target molecule contained within a test mixture, such as a bodily fluid. The target molecules include, but are not limited to, proteins (cellular, viral, bacterial, etc.) hormones, sugars, metabolic byproducts, cofactor, and intermediates, drugs, and toxins. Contacting the test mixture with the biochip leads to the binding of a target molecule to its cognate nucleic acid ligand. The biochip may then be contacted with a reagent(s) that reacts covalently with proteins and not with nucleic acids. Each protein target in the test mixture may then detected by detecting the presence of the reagent at the appropriate address on the biochip.

摘要翻译： 公开了一种核酸配体“生物芯片”，其由以空间限定的方式连接一个或多个特定核酸配体的固体支持物组成。 每个核酸配体特异性地并且强烈地结合到测试混合物（例如体液）中所含的特定靶分子。 靶分子包括但不限于蛋白质（细胞，病毒，细菌等）激素，糖，代谢副产物，辅因子和中间体，药物和毒素。 将测试混合物与生物芯片接触导致靶分子与其同源核酸配体的结合。 然后生物芯片可以与与蛋白质共价反应的试剂与不与核酸反应的试剂接触。 然后可以通过检测生物芯片上适当地址处的试剂的存在来检测测试混合物中的每个蛋白质靶标。